We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Johnson & Johnson (JNJ) Laps the Stock Market: Here's Why
Read MoreHide Full Article
Johnson & Johnson (JNJ - Free Report) closed the latest trading day at $157.89, indicating a +1.87% change from the previous session's end. This move outpaced the S&P 500's daily gain of 0.24%. At the same time, the Dow added 0.16%, and the tech-heavy Nasdaq gained 0.08%.
Shares of the world's biggest maker of health care products witnessed a gain of 4.62% over the previous month, beating the performance of the Medical sector with its gain of 3.63% and the S&P 500's gain of 2.37%.
Market participants will be closely following the financial results of Johnson & Johnson in its upcoming release. The company is predicted to post an EPS of $2.59, indicating a 4.43% decline compared to the equivalent quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $21.66 billion, up 1.29% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $10.58 per share and a revenue of $90.03 billion, signifying shifts of +6.01% and +1.36%, respectively, from the last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Johnson & Johnson. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 1% higher. At present, Johnson & Johnson boasts a Zacks Rank of #3 (Hold).
Digging into valuation, Johnson & Johnson currently has a Forward P/E ratio of 14.65. This signifies a premium in comparison to the average Forward P/E of 12.51 for its industry.
It's also important to note that JNJ currently trades at a PEG ratio of 2.49. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 1.35.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 174, finds itself in the bottom 31% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow JNJ in the coming trading sessions, be sure to utilize Zacks.com.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Johnson & Johnson (JNJ) Laps the Stock Market: Here's Why
Johnson & Johnson (JNJ - Free Report) closed the latest trading day at $157.89, indicating a +1.87% change from the previous session's end. This move outpaced the S&P 500's daily gain of 0.24%. At the same time, the Dow added 0.16%, and the tech-heavy Nasdaq gained 0.08%.
Shares of the world's biggest maker of health care products witnessed a gain of 4.62% over the previous month, beating the performance of the Medical sector with its gain of 3.63% and the S&P 500's gain of 2.37%.
Market participants will be closely following the financial results of Johnson & Johnson in its upcoming release. The company is predicted to post an EPS of $2.59, indicating a 4.43% decline compared to the equivalent quarter last year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $21.66 billion, up 1.29% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $10.58 per share and a revenue of $90.03 billion, signifying shifts of +6.01% and +1.36%, respectively, from the last year.
It's also important for investors to be aware of any recent modifications to analyst estimates for Johnson & Johnson. These revisions typically reflect the latest short-term business trends, which can change frequently. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.
Based on our research, we believe these estimate revisions are directly related to near-team stock moves. To utilize this, we have created the Zacks Rank, a proprietary model that integrates these estimate changes and provides a functional rating system.
The Zacks Rank system ranges from #1 (Strong Buy) to #5 (Strong Sell). It has a remarkable, outside-audited track record of success, with #1 stocks delivering an average annual return of +25% since 1988. Within the past 30 days, our consensus EPS projection has moved 1% higher. At present, Johnson & Johnson boasts a Zacks Rank of #3 (Hold).
Digging into valuation, Johnson & Johnson currently has a Forward P/E ratio of 14.65. This signifies a premium in comparison to the average Forward P/E of 12.51 for its industry.
It's also important to note that JNJ currently trades at a PEG ratio of 2.49. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 1.35.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry, currently bearing a Zacks Industry Rank of 174, finds itself in the bottom 31% echelons of all 250+ industries.
The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
To follow JNJ in the coming trading sessions, be sure to utilize Zacks.com.